Patent ID: 9688754
Date: 2017-06-27
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of reducing plasma cortisol levels in a subject in need thereof comprising administering to said subject an effective amount of an anti-human adrenocorticotrophic hormone (ACTH) monoclonal antibody, or antigen-binding fragment thereof, comprising three heavy- and three light-chain complementarity-determining regions (CDRs) selected from: (a) the Ab1 heavy- and light-chain CDRs of SEQ ID NOs: 4, 6, 8, 24, 26, and 28; (b) the Ab2 heavy- and light-chain CDRs of SEQ ID NOs: 44, 46, 48, 64, 66, and 68; (c) the Ab3 heavy- and light-chain CDRs of SEQ ID NOs: 84, 86, 88, 104, 106, and 108; (d) the Ab4 heavy- and light-chain CDRs of SEQ ID NOs: 124, 126, 128, 144, 146, and 148; (e) the Ab10 heavy- and light-chain CDRs of SEQ ID NOs: 324, 326, 328, 344, 346, and 348; (f) the Ab11 heavy- and light-chain CDRs of SEQ ID NOs: 364, 366, 368, 384, 386, and 388; (g) the Ab12 heavy- and light-chain CDRs of SEQ ID NOs: 404, 406, 408, 424, 426, and 428; (h) the Ab1.H heavy- and light-chain CDRs of SEQ ID NOs: 444, 446, 448, 464, 466, and 468; (i) the Ab2.H heavy- and light-chain CDRs of SEQ ID NOs: 484, 486, 488, 504, 506, and 508; (j) the Ab3.H heavy- and light-chain CDRs of SEQ ID NOs: 524, 526, 528, 544, 546, and 548; (k) the Ab4.H heavy- and light-chain CDRs of SEQ ID NOs: 564, 566, 568, 584, 586, and 588; (l) the Ab10.H heavy- and light-chain CDRs of SEQ ID NOs: 724, 726, 728, 744, 746, and 748; (m) the Ab11.H heavy- and light-chain CDRs of SEQ ID NOs: 764, 766, 768, 784, 786, and 788; (n) the Ab11A.H heavy- and light-chain CDRs of SEQ ID NOs: 804, 806, 808, 824, 826, and 828; and (o) the Ab12H heavy- and light-chain CDRs of SEQ ID NOs: 844, 846, 848, 864, 866, and 868.